Week Ending March 8, 2022

FDA Approves Opdivo-Chemotherapy Regimen for Pre-Surgical Treatment of Non-Small Cell Lung Cancer
“The Food and Drug Administration (FDA) approved the use of Opdivo (nivolumab) plus a platinum-doublet chemotherapy regimen as a pre-surgical treatment option for adults with resectable — defined as tumors greater than or equal to 4 centimeters in size or node positive — non-small cell lung cancer.”

The Lung Cancer Registry Launches New International Survey Focused on Experiences and Mental Health of Caregivers
“Through the first step of information collection, GO2 Foundation for Lung Cancer attempts to provide real tailored support programs to the caregivers of people around the world living with lung cancer”

Lung Cancer Research Foundation and MET Crusaders Announce Partnership
“NEW YORK, Feb. 28, 2022 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) and MET Crusaders are pleased to announce a partnership aimed at funding much needed MET cancer research. Together they pledge to fund two projects in 2022 that focus on this specific oncogene.”

When to Try Pulmonary Rehabilitation for Lung Cancer
“Surgery, chemotherapy, and radiation are the foundations of lung cancer treatment. These therapies can slow or stop cancer. But they don’t address things like treatment side effects or the emotional and physical toll that cancer can take on you.”

Complementary therapies for lung cancer
“Both lung cancer and its treatments can cause symptoms that diminish quality of life. Complementary therapies may help relieve these symptoms, but they do not treat the underlying cancer.”

Biodesix Announces Impactful Clinical Data on the Primary Immune Response (PIR) Test at the IASLC 2022 Therapies of Lung Cancer Meeting
“BOULDER, Colo.–(BUSINESS WIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.”